Cost-Effectiveness Analysis of Tocilizumab Subcutaneous As First Line Biologic Monotherapy for Rheumatoid Arthritis Management In Greece
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1971
https://www.valueinhealthjournal.com/article/S1098-3015(15)04047-4/fulltext
Title :
Cost-Effectiveness Analysis of Tocilizumab Subcutaneous As First Line Biologic Monotherapy for Rheumatoid Arthritis Management In Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04047-4&doi=10.1016/j.jval.2015.09.1971
First page :
A671
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1865